Hormonal Treatment of Endocrine-Dependent Tumours: Clinical Considerations

  • F. Boccardo
  • E. Verri
  • P. Guglielmini
Conference paper


Today hormone therapies still aim at interfering with the mitogenic action of sexual hormones. Basically this aim can be attained through the inhibition of the synthesis of steroid hormones. In this way target cells are spared the trophic stimulus represented by those hormones (“ablative hormone thera-py”). Otherwise, it is possible to affect the link between sexual hormones and their receptors, and to interfere with one or more stages of the transcription process (“competitive hormone therapy”).


Breast Cancer Prostate Cancer Endometrial Cancer Clin Oncol Advanced Breast Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. No authors (1995). Maximum androgen blockade in advanced prostate cancer: an overview of 22 randomised trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists’ Collaborative Group. Lancet, 346, 265–269.Google Scholar
  2. No authors (2000). Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists’ Collaborative Group. Lancet, 355, 1491–1498.Google Scholar
  3. Akaza H., Homma Y., Okada K., Yokoyama M., Usami M., Hirao Y., Tsushima T., Ohashi Y. and Aso Y. (2003). A prospective and randomized study of primary hormonal therapy for patients with localized or locally advanced prostate cancer unsuitable for radical prostatectomy: results of the 5-year follow-up. BJU Int, 91, 33–36.PubMedCrossRefGoogle Scholar
  4. Alberts S.R. and Blute M.L. (2001). Chemoprevention for prostatic carcinoma: the role of flutamide in patients with prostatic intraepithelial neoplasia. Urology, 57, 188–190.PubMedCrossRefGoogle Scholar
  5. Asbury R.F., Brunetto V.L., Lee R.B., Reid G. and Rocereto T.F. (2002). Goserelin acetate as treatment for recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Am J Clin Oncol, 25, 557–560.PubMedCrossRefGoogle Scholar
  6. Aus G., Abrahamsson P.A., Ahlgren G., Hugosson J., Lundberg S., Schain M., Schelin S. and Pedersen K. (2002). Three-month neoadjuvant hormonal therapy before radical prostatectomy: a 7-year follow-up of a randomized controlled trial. BJU Int, 90, 561–566.PubMedCrossRefGoogle Scholar
  7. Baekelandt M. (2002). Hormonal treatment of endometrial carcinoma. Expert Rev Anticancer Ther, 2, 106–112.PubMedCrossRefGoogle Scholar
  8. Baum M. (2001). The ATAC (Arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trial in postmenopausal women. Breast Cancer Res Treat, 69, 210.Google Scholar
  9. Blarney R.W. (2002). Guidelines on endocrine therapy of breast cancer. EUSOMA. Eur J Cancer, 38, 615–634.CrossRefGoogle Scholar
  10. Boccardo F., Barichello M., Battaglia M., Carmignani G., Comeri G., Ferraris V., Lilliu S., Montefiore F., Portoghese R, Cortellini P., Rigatti P., Usai E. and Rubagotti A. (2002). Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer: updated results of a multicentric Trial. Eur Urol, 42, 481–490.PubMedCrossRefGoogle Scholar
  11. Boccardo R., Pace M., Rubagotti A., Guarneri D., Decensi A., Oneto F., Martorana G., Giuliani L., Selvaggi R, Battaglia M. et al. (1993). Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group. Eur J Cancer, 29A, 1088–1093.PubMedCrossRefGoogle Scholar
  12. Boccardo R., Rubagotti A., Amoroso D., Mesiti M., Romeo D., Caroti C., Farris A., Cruciani G., Villa E., Schieppati G. and Mustacchi G. (2001). Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study. J Clin Oncol, 19, 4209–4215.PubMedGoogle Scholar
  13. Boccardo R., Rubagotti A., Barichello M., Battaglia M., Carmignani G., Comeri G., Conti G., Cruciani G., Dammino S., Delliponti U., Ditonno P., Ferraris V., Lilliu S., Montefiore R, Portoghese R and Spano G. (1999). Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study. J Clin Oncol, 17, 2027–2038.PubMedGoogle Scholar
  14. Boccardo R, Rubagotti A., Perrotta A., Amoroso D., Balestrero M., De Matteis A., Zola P., Sismondi P., Francini G., Petrioli R. et al. (1994). Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol, 5, 337–342.PubMedGoogle Scholar
  15. Bolla M., de Reijke T.M., Zurlo A. and Collette L. (2002). Adjuvant hormone therapy in locally advanced and localized prostate cancer: three EORTC trials. Front Radiat Ther Oncol, 36, 81–86.PubMedCrossRefGoogle Scholar
  16. Bonneterre J., Thurlimann B., Robertson J. R, Krzakowski M., Mauriac L., Koralewski P., Vergote I., Webster A., Steinberg M. and von Euler M. (2000). Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol, 18, 3748–3759.PubMedGoogle Scholar
  17. Buzdar A.U. (2001). Endocrine therapy in the treatment of metastatic breast cancer. Semin Oncol, 28, 291–304.PubMedCrossRefGoogle Scholar
  18. Buzdar A.U. (2002). Superior efficacy of letrozole versus tamoxifen as first-line therapy. J Clin Oncol, 20, 876–878.PubMedGoogle Scholar
  19. Buzdar A.U., Jonat W., Howell A., Jones S.E., Blomqvist CR, Vogel C.L., Eiermann W., Wolter J.M., Steinberg M., Webster A. and Lee D. (1998). Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer, 83, 1142–1152.PubMedCrossRefGoogle Scholar
  20. Carswell C.I. and Figgitt D.P. (2002). Bicalutamide: in early-stage prostate cancer. Drugs, 62, 2471–2479; discussion 2480–2481.PubMedCrossRefGoogle Scholar
  21. Ciatto S., Cirillo A., Confortini M. and Cardillo Cde L. (1996). Tamoxifen as primary treatment of breast cancer in elderly patients. Neoplasma, 43, 43–45.PubMedGoogle Scholar
  22. Cranney A., Tugwell P., Zytaruk N., Robinson V., Weaver B., Adachi J., Wells G., Shea B. and Guyatt G. (2002). Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis. Endocr Rev, 23, 524–528.PubMedCrossRefGoogle Scholar
  23. Decensi A.U., Boccardo F., Guarneri D., Positano N., Paoletti M.C., Costantini M., Martorana G. and Giuliani L. (1991). Monotherapy with nilutamide, a pure nonsteroidal anti-androgen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project. J Urol, 146, 377–381.PubMedGoogle Scholar
  24. Desai A., Stadler W.M. and Vogelzang N.J. (2001). Nilutamide: possible utility as a second-line hormonal agent. Urology, 58, 1016–1020.PubMedCrossRefGoogle Scholar
  25. Dixon J.M., Love CD., Bellamy CO., Cameron D.A., Leonard R.C, Smith H. and Miller W.R. (2001). Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat, 66, 191–199.PubMedCrossRefGoogle Scholar
  26. Dombernowsky P., Smith I., Falkson G., Leonard R., Panasci L., Bellmunt J., Bezwoda W, Gardin G., Gudgeon A., Morgan M., Fornasiero A., Hoffmann W, Michel J., Hatschek T., Tjabbes T, Chaudri H.A., Hornberger U. and Trunet PR (1998). Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol, 16, 453–461.PubMedGoogle Scholar
  27. Foudraine N.A., Verhoef L.C and Burghouts J.T. (1992). Tamoxifen as sole therapy for primary breast cancer in the elderly patient. Eur J Cancer, 28A, 900–903.PubMedCrossRefGoogle Scholar
  28. Fowler J.E. Jr, Bigler S.A., White P.C. and Duncan WL. (2002). Hormone therapy for locally advanced prostate cancer. J Urol, 168, 546–549.PubMedCrossRefGoogle Scholar
  29. Fujikawa K., Matsui Y., Fukuzawa S. and Takeuchi H. (2000). Prostate-specific antigen levels and clinical response to flutamide as the second hormone therapy for hormone-refractory prostate carcinoma. Eur Urol, 37, 218–222.PubMedCrossRefGoogle Scholar
  30. Gleave M., Bruchovsky N., Bowden M., Goldenberg S.L. and Sullivan L.D. (1994). Intermittent androgen suppression prolongs time to androgen-independent progression in the LNCaP prostate tumor model. J Urol, 151, 457A.Google Scholar
  31. Gleave M.E., Goldenberg S.L., Chin J.L., Warner J., Saad F., Klotz L.H., Jewett M., Kassabian V, Chetner M., Dupont C. and Van Rensselaer S. (2001). Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol, 166, 500–506; discussion 506–507.PubMedCrossRefGoogle Scholar
  32. Goldenberg S.L., Bruchovsky N., Gleave M.E., Sullivan L.D. and Akakura K. (1995)-Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report. Urology, 45, 839–844; discussion 844–845.PubMedCrossRefGoogle Scholar
  33. Goldhirsch A., Glick J.H., Gelber R.D., Coates A.S. and Senn H.J. (2001). Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer. J Clin Oncol, 19, 3817–3827.PubMedGoogle Scholar
  34. Hara T., Miyazaki J., Araki H., Yamaoka M., Kanzaki N., Kusaka M. and Miyamoto M. (2003). Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res, 63, 149–153.PubMedGoogle Scholar
  35. Holli K. (2002). Tamoxifen versus toremifene in the adjuvant treatment of breast cancer Eur J Cancer, 38 (Suppl 6), S37–S38.PubMedCrossRefGoogle Scholar
  36. Howell A. (2001). Future use of selective estrogen receptor modulators and aromatase inhibitors. Clin Cancer Res, 7, 44028–44108; discussion 4411S–4412S.Google Scholar
  37. Imai M., Iobo T., Sato R., Kawaguchi M. and Kuramoto H. (2001). Medroxyprogesterone acetate therapy for patients with adenocarcinoma of the endometrium who wish to preserve the uterus-usefulness and limitations. Eur J Gynaecol Oncol, 22, 217–220.PubMedGoogle Scholar
  38. Isurugi K., Fukutani K., Ishida H. and Hosoi Y. (1980). Endocrine effects of cyproterone acetate in patients with prostatic cancer. J Urol, 123, 180–183.PubMedGoogle Scholar
  39. Iversen P., Tyrrell C.J., Kaisary A.V., Anderson J.B., Baert J., Tammela T., Chamberlain M., Carroll K., Getting-Smith K. and Blackledge G.R. (1998). Casodex (bicalutamide) 150-mg monotherapy compared with castration in patients with previously untreated nonmetastatic prostate cancer: results from two multicenter randomized trials at a median follow-up of 4 years. Urology, 51, 389–396.PubMedCrossRefGoogle Scholar
  40. Iversen P., Tyrrell C.J., Kaisary A.V., Anderson J.B., Van Poppel H., Tammela T.L., Chamberlain M., Carroll K. and Melezinek I. (2000). Bicalutamide monotherapy compared with castration in patients with nonmetastatic locally advanced prostate cancer: 6.3 years of followup. J Urol, 164, 1579–1582.PubMedCrossRefGoogle Scholar
  41. Jacobi G.H., Altwein J.E., Kurth K.H., Basting R. and Hohenfellner R. (1980). Treatment of advanced prostatic cancer with parenteral cyproterone acetate: a phase III randomised trial. Br J Urol, 52, 208–215.PubMedCrossRefGoogle Scholar
  42. Jones S.E. (2002). A new estrogen receptor antagonist-an overview of available data. Breast Cancer Res Treat, 75 (Suppl 1), S19–S21; discussion S33–S35.PubMedCrossRefGoogle Scholar
  43. Kelly W.K. (1998). Endocrine withdrawal syndrome and its relevance to the management of hormone refractory prostate cancer. Eur Urol, 34 (Suppl 3), 18–23.PubMedCrossRefGoogle Scholar
  44. Kelly W.K. and Scher H.I. (1993). Prostate specific antigen decline after anti-androgen withdrawal: the flutamide withdrawal syndrome. J Urol, 149, 607–609.PubMedGoogle Scholar
  45. Kim Y.B., Holschneider C.H., Ghosh K., Nieberg R.K. and Montz E.J. (1997). Progestin alone as primary treatment of endometrial carcinoma in premenopausal women. Report of seven cases and review of the literature. Cancer, 79, 320–327.PubMedCrossRefGoogle Scholar
  46. Kirby R.S. (1996). Recent advances in the medical management of prostate cancer. Br J Clin Pract, 50, 88–93.PubMedGoogle Scholar
  47. Klijn J.G., Beex L.V., Mauriac L., van Zijl J.A., Veyret C., Wildiers J., Jassem J., Piccart M., Burghouts J., Becquart D., Seynaeve C., Mignolet E and Duchateau I. (2000). Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst, 92, 903–911.PubMedCrossRefGoogle Scholar
  48. Klijn J.G., Blarney R.W., Boccardo E, Tominaga T., Duchateau L. and Sylvester R. (2001). Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta -analysis of four randomized trials. J Clin Oncol, 19, 343–353.PubMedGoogle Scholar
  49. Labrie F. (2002). Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol, 198, 77–87.PubMedCrossRefGoogle Scholar
  50. Lawton C.A., Winter K., Murray K., Machtay M., Mesic J.B., Hanks G.E., Coughlin C.T. and Pilepich M.V. (2001). Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol BioI Phys, 49, 937–946.CrossRefGoogle Scholar
  51. Loibl S., von Minckwitz G. and Kaufmann M. (2002). Adjuvant hormone therapy following primary therapy for endometrial cancer. Eur J Cancer, 38 (Suppl 6), S41–S43.PubMedCrossRefGoogle Scholar
  52. Lonning P.E., Bajetta E., Murray R., Tubiana-Hulin M., Eisenberg P.D., Mickiewicz E., Celio L., Pitt P., Mita M., Aaronson N.K., Fowst C., Arkhipov A., di Salle E., Polli A. and Massimini G. (2000). Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol, 18, 2234–2244.PubMedGoogle Scholar
  53. Martin-Hirsch P.L., Lilford R.J. and Jarvis G.J. (1996). Adjuvant progestagen therapy for the treatment of endometrial cancer: review and meta-analyses of published randomised controlled trials. Eur J Obstet Gynecol Reprod Biol, 65,201–207.PubMedCrossRefGoogle Scholar
  54. McLeod D., Zinner N., Tomera K., Gleason D., Fotheringham N., Campion M. and Garnick M.B. (2001). A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology, 58,756–761.PubMedCrossRefGoogle Scholar
  55. Meng M.V., Grossfeld G.D., Carroll RR. and Small E.J. (2002). Neoadjuvant strategies for prostate cancer prior to radical prostatectomy. Semin Urol Oncol, 20,10–18.PubMedCrossRefGoogle Scholar
  56. Messing E.M., Manola J., Sarosdy M., Wilding G., Crawford E.D. and Trump D. (1999). Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. N Engl J Med, 341,1781–1788.PubMedCrossRefGoogle Scholar
  57. Michaud L.B. and Buzdar A.U. (2000). Complete estrogen blockade for the treatment of metastatic and early stage breast cancer. Drugs Aging, 16, 261–271.PubMedCrossRefGoogle Scholar
  58. Morris C. and Wakeling A. (2002). Fulvestrant (‘Faslodex’)-a new treatment option for patients progressing on prior endocrine therapy. Endocr Relat Cancer, 9, 267–276.PubMedCrossRefGoogle Scholar
  59. Murray R. and Pitt P. (1995). Aromatase inhibition with 4-OHAndrostenedione after prior aromatase inhibition with aminoglutethimide in women with advanced breast cancer. Breast Cancer Res Treat, 35,249–253.PubMedCrossRefGoogle Scholar
  60. Mustacchi G., Milani S., Pluchinotta A., De Matteis A., Rubagotti A. and Perrota A. (1994). Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: The GRETA Trial. Group for Research on Endocrine Therapy in the Elderly. Anticancer Res, 14,2197–2200.PubMedGoogle Scholar
  61. Nabholtz J.M., Buzdar A., Pollak M., Harwin W., Burton G., Mangalik A., Steinberg M., Webster A. and von Euler M. (2000). Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol, 18, 3758–3767.PubMedGoogle Scholar
  62. Neri R. and Kassem N. (1984). Biological and clinical properties of anti-androgens. In Progress in Cancer Research and Therapy, eds. Bresciani F et al, 31, pp. 507–518, New York, Raven Press.Google Scholar
  63. Pagani O., O’Neill A., Castiglione M., Gelber R.D., Goldhirsch A., Rudenstam CM., Lindtner J., Collins J., Crivellari D., Coates A., Cavalli F., Thurlimann B., Simoncini E., Fey M., Price K. and Senn H.J. (1998). Prognostic impact of amenorrhoea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of the International Breast Cancer Study Group (IBCSG) Trial VI. Eur J Cancer, 34, 632–640.PubMedCrossRefGoogle Scholar
  64. Paul R. and Breul J. (2000). Anti-androgen withdrawal syndrome associated with prostate cancer therapies: incidence and clinical significance. Drug Saf, 23,381–390.PubMedCrossRefGoogle Scholar
  65. Pavone-Macaluso M., de Voogt H.J., Viggiano G., Barasolo E., Lardennois B., de Pauw M. and Sylvester R. (1986). Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol, 136, 624–631.PubMedGoogle Scholar
  66. Pilepich M.V., Caplan R., Byhardt R.W., Lawton CA., Gallagher M.J., Mesic J.B., Hanks G.E., Coughlin CT., Porter A., Shipley W.U. and Grignon D. (1997). Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol, 85-31. J Clin Oncol, 15,1013–1021.PubMedGoogle Scholar
  67. Pilepich M.V., Winter K., John M.J., Mesic J.B., Sause W, Rubin P., Lawton C, Machtay M. and Grignon D. (2001). Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate. Int J Radiât Oncol Biol Phys, 50,1243–1252.PubMedCrossRefGoogle Scholar
  68. Plowman P.N., Nicholson R.I. and Walker K.J. (1986). Remission of postmenopausal breast cancer during treatment with the luteinising hormone releasing hormone agonist ICI 118630. Br J Cancer, 54, 903–909.PubMedCrossRefGoogle Scholar
  69. Podczaski E. and Mortel R. (2001). Hormonal treatment of endometrial cancer: past, present and future. Best Pract Res Clin Obstet Gynaecol, 15, 469–489.PubMedCrossRefGoogle Scholar
  70. Powles T.J. (2002). Anti-oestrogenic prevention of breast cancer—the make or break point. Nat Rev Cancer, 2, 787–794.PubMedCrossRefGoogle Scholar
  71. Pukkala E., Kyyronen P., Sankila R. and Holli K. (2002). Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study. Int J Cancer, 100, 337–341.PubMedCrossRefGoogle Scholar
  72. Ragaz J. (2001). Adjuvant trials of aromatase inhibitors: determining the future landscape of adjuvant endocrine therapy. J Steroid Biochem Mol Biol, 79, 133–141.PubMedCrossRefGoogle Scholar
  73. Robertson, J. F. (2002). Estrogen receptor downregulators: new antihormonal therapy for advanced breast cancer. Clin Ther, 24 (Suppl A), A17–A30.PubMedCrossRefGoogle Scholar
  74. Schellhammer R.R, Sharifi R., Block N.L., Soloway M.S., Venner P.M., Patterson A.L., Sarosdy M.R, Vogelzang N.J., Schellenger J.J. and Kolvenbag G.J. (1997). Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group. Urology, 50, 330–336.PubMedCrossRefGoogle Scholar
  75. Shipley W.U., Lu J.D., Pilepich M.V., Heydon K., Roach M., Wolkov H.B., Sause W.T., Rubin P., Lawton C.A. and Machtay M. (2002). Effect of a short course of neoadjuvant hormonal therapy on the response to subsequent androgen suppression in prostate cancer patients with relapse after radiotherapy: a secondary analysis of the randomized protocol RTOG 86–10. Int J Radiât Oncol Biol Phys, 54, 1302–1310.PubMedCrossRefGoogle Scholar
  76. Steiner M.S., Raghow S. and Neubauer B.L. (2001). Selective estrogen receptor modulators for the chemoprevention of prostate cancer. Urology, 57, 68–72.PubMedCrossRefGoogle Scholar
  77. Thurlimann B., Paridaens R., Serin D., Bonneterre J., Roche H., Murray R., di Salle E., Lanzalone S., Zurlo M.G. and Piscitelli G. (1997). Third-line hormonal treatment with exemestane in postmenopausal patients with advanced breast cancer progressing on aminoglutethimide: a phase II multicentre multinational study. Exemestane Study Group. Eur J Cancer, 33, 1767–1773.PubMedCrossRefGoogle Scholar
  78. Trachtenberg J., Gittleman M., Steidle C., Barzell W., Friedel W., Pessis D., Fotheringham N., Campion M. and Garnick M.B. (2002). A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily anti-androgen in men with prostate cancer. J Urol, 167, 1670–1674.PubMedCrossRefGoogle Scholar
  79. Tyrrell C.J. (1992). Casodex: a pure non-steroidal anti-androgen used as monotherapy in advanced prostate cancer. Prostate Suppl, 4, 97–104.PubMedCrossRefGoogle Scholar
  80. Tyrrell C.J., Kaisary A.V., Iversen P., Anderson J.B., Baert L., Tammela T., Chamberlain M., Webster A. and Blackledge G. (1998). A randomised comparison of ’Casodex’ (bicalutamide) 150 mg monotherapy versus castration in the treatment of metastatic and locally advanced prostate cancer. Eur Urol, 33, 447–456.PubMedCrossRefGoogle Scholar
  81. van der Kwast T. H., Labrie F. and Tetu B. (1999). Prostatic intraepithelial neoplasia and endocrine manipulation. Eur Urol, 35, 508–510.PubMedCrossRefGoogle Scholar
  82. Veronesi U., Maisonneuve P., Rotmensz N., Costa A., Sacchini V., Travaglini R., D’Aiuto G., Lovison R, Gucciardo G., Muraca M.G., Pizzichetta M.A., Conforti S., Decensi A., Robertson C. and Boyle P. (2003). Italian randomized trial among women with hysterectomy: tamoxifen and hormone-dependent breast cancer in high-risk women. J Natl Cancer Inst, 95, 160–165.PubMedCrossRefGoogle Scholar
  83. Vici P., Veltri E., Carpano S., Di Lauro L. and Lopez M. (1991). [Buserelin therapy in postmenopausal patients with advanced breast carcinoma]. Clin Ter, 136, 195–199.PubMedGoogle Scholar
  84. Waxman J.H., Harland S.J., Coombes R.C, Wrigley RR, Malpas J.S., Powles T. and Lister T.A. (1985). The treatment of postmenopausal women with advanced breast cancer with buserelin. Cancer Chemother Pharmacol, 15, 171–173.PubMedCrossRefGoogle Scholar
  85. Willsher P.C., Robertson J.F., Armitage N.C., Morgan D.A., Nicholson R.I. and Blarney R.W. (1996). Locally advanced breast cancer: long-term results of a randomized trial comparing primary treatment with tamoxifen or radiotherapy in post-menopausal women. Eur J Surg Oncol, 22, 34–37.PubMedCrossRefGoogle Scholar
  86. Wirth M. (2001). Delaying/reducing the risk of clinical tumour progression after primary curative procedures. Eur Urol, 40 (Suppl 2), 17–23.PubMedCrossRefGoogle Scholar
  87. Zincke H., Lau W., Bergstralh E. and Blute M.L. (2001). Role of early adjuvant hormonal therapy after radical prostatectomy for prostate cancer. J Urol, 166, 2208–2215.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Italia 2003

Authors and Affiliations

  • F. Boccardo
  • E. Verri
  • P. Guglielmini

There are no affiliations available

Personalised recommendations